John Jacob Abel the position of chair of the department until he retired at the age of 75 in 1932. Ever since his early years in Europe, Abel showed great interest in isolating pure form of internal gland hormones. The first work that led to his international reputation as a pharmacologist and biochemist was the isolation of epinephrine from adrenal medulla. However, he was only able to isolate a monobenzoyl derivative of epinephrine. While he was improving his processes on decomposing the benzoyl derivative to obtain salts of epinephrine using saponification, a Japanese chemist J. Takamine, who had visited his lab, was able
Growth hormone–releasing hormone been used in the diagnosis of deficiencies in growth hormone secretion. Tesamorelin, under the trade name Egrifta, received U.S. Food and Drug Administration approval in 2010 for the treatment of lipodystrophy in HIV patients under highly active antiretroviral therapy, and, in 2011, was investigated for effects on certain cognitive tests in the elderly. As a category, the use of GHRH analogs by professional athletes may be prohibited by restrictions on doping in sport because they act as growth hormone secretagogues. Growth hormone–releasing hormone Growth hormone–releasing hormone (GHRH), also known as somatocrinin or by several other names in its endogenous forms